Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia
- Sponsor:
- Merck
- Sponsor Study ID:
- MK-3543-006
- CTO #:
- 104108
- NCT Number:
- NCT06079879
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Other Hematopoietic
- Study Objectives:
- To compare bomedemstat to best available therapy with respect to DCHR. To compare bomedemstat to best available therapy with respect to change in fatigue score based on MFSAF v4.0.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Coltoff, Alexander, at coltoff@musc.edu .
- Study Coordinator, Ward, Sarah, at saw306@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina